Who Paid My Doc
Carolyn Fleming Fruci
Critical Care Medicine Williamsburg, VA Medical Doctor
NPI 1952341653 CMS profile 134240
400 Sentara Cir Ste 320, Williamsburg, VA 23188
General payments
$3,291
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,428
Through program year 2025, Carolyn Fleming Fruci of Williamsburg, VA is reported in the CMS Open Payments database as having received $3,291 across 145 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,428 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 81st percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $50 | 1 | |
| 2023 | General | $870 | 10 | |
| 2022 | General | $249 | 14 | |
| 2021 | General | $312 | 17 | |
| 2020 | General | $538 | 33 | |
| 2019 | General | $1,272 | 70 |
Beside peers
- Carolyn Fleming Fruci
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Carolyn Fleming Fruci were reported at $50. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Carolyn Fleming Fruci | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,272 | $149 | $51–$535 | $163 |
| 2020 | $538 | $110 | $30–$325 | $114 |
| 2021 | $312 | $125 | $34–$403 | $132 |
| 2022 | $249 | $157 | $49–$582 | $149 |
| 2023 | $870 | $162 | $56–$621 | $160 |
| 2024 | $0 | $168 | $53–$634 | $164 |
| 2025 | $50 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
68
Drug cost
$20,412
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 17 | $10,816 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 13 | $8,596 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 38 | $1,000 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$12,724
Medicare patients
65
Services billed
104
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 68% | |
| Diabetes | 62% | |
| Chronic kidney disease | 55% | |
| Ischemic heart disease | 51% | |
| Atrial fibrillation | 48% | |
| Arthritis | 42% | |
| Depression | 35% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
145 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Virginia
Oksana Shlobin
Critical Care Medicine · Falls Church, VA
Matthew Williams
Critical Care Medicine · Annandale, VA
Sami Abdul Jawad
Critical Care Medicine · Falls Church, VA
Rajiv Malhotra
Critical Care Medicine · Richmond, VA
Thomas Bouder
Critical Care Medicine · Winchester, VA
Christopher King
Critical Care Medicine · Falls Church, VA
Related records
Critical Care Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.